Regentis Biomaterials grants 24,826 stock options

Regentis Biomaterials Ltd. granted Director Susan Alpert an employee stock option for 24,826 Ordinary Shares at an exercise price of $2.16 per share.

Rhea-AI Filing Summary

Regentis Biomaterials Ltd. granted Director Susan Alpert an employee stock option for 24,826 Ordinary Shares at an exercise price of $2.16 per share. The grant, approved by the board on June 4, 2026 and subject to shareholder approval, became effective after shareholders approved it on July 9, 2026. The options vest in twelve quarterly installments starting September 4, 2026 and continue through June 4, 2029, and expire on June 4, 2036. Following this grant, Alpert holds options for 24,826 shares directly.

Insider Trade Summary

Grant/Award: 24,826 shares

Grant/Award 1 txn

Insider Alpert Susan PHD MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1, F2	24,826	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 24,826 contracts (Direct)

Footnotes (2)

1. F1. This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
2. F2. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029.

Key Figures

Options Granted: 24,826 options Exercise Price: $2.1600 per share Total Options After Grant: 24,826 options +3 more

6 metrics

Options Granted 24,826 options Employee stock option grant to Director Susan Alpert

Exercise Price $2.1600 per share Conversion or exercise price of the employee stock option

Total Options After Grant 24,826 options Total derivative securities held following the reported transaction

First Vesting Date September 4, 2026 First 1/12 of options vest on this date

Full Vesting Date June 4, 2029 Options fully vest on the third anniversary of the grant date

Expiration Date June 4, 2036 Expiration date of the employee stock option

Key Terms

Employee Stock Option (Right to Buy), exercise price, vest on a quarterly basis, subject to shareholder approval, +1 more

5 terms

Employee Stock Option (Right to Buy) financial

"security title is listed as Employee Stock Option (Right to Buy)"

exercise price financial

"conversion or exercise price of $2.1600 per share is specified"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest on a quarterly basis financial

"options grant shall vest on a quarterly basis, with one-twelfth vesting"

subject to shareholder approval regulatory

"option grant was approved by the Board of Directors, subject to shareholder approval"

expiration date financial

"derivative security shows an expiration date of 2036-06-04"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RGNT director Susan Alpert report?

Director Susan Alpert reported a grant of employee stock options for 24,826 Ordinary Shares of RGNT. The options carry a $2.16 exercise price, were granted as compensation, and do not reflect any open-market purchase or sale of shares.

How many RGNT options were granted to Susan Alpert and at what price?

Susan Alpert received an option covering 24,826 Ordinary Shares of RGNT at an exercise price of $2.16 per share. The grant price reflects the cost to exercise the options in the future, not an immediate cash transaction.

What is the vesting schedule of Susan Alpert’s RGNT stock options?

The options vest quarterly over three years, with 1/12 vesting on September 4, 2026, and another 1/12 on the last day of each subsequent three-month period. Vesting continues until June 4, 2029, subject to her continuous employment.

When do Susan Alpert’s RGNT options expire and when can they first be exercised?

The options are first scheduled to vest on September 4, 2026, after which vested portions may be exercisable subject to plan terms. The entire option position has an expiration date of June 4, 2036, after which any unexercised options lapse.

Did the RGNT option grant to Susan Alpert require shareholder approval?

Yes. The option grant was approved by the board on June 4, 2026, subject to shareholder approval. Shareholders subsequently approved it on July 9, 2026, at which point the grant terms became effective as described.

How many RGNT options does Susan Alpert hold after this grant?

After this grant, Susan Alpert holds 24,826 stock options directly, each relating to one Ordinary Share of RGNT. This total reflects the full amount of the new grant as her derivative holdings reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alpert Susan PHD MD

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYHEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	$2.16	07/09/2026		A		24,826		09/04/2026	06/04/2036	Ordinary Shares	24,826	$0	24,826	D

Explanation of Responses:

1. This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

2. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029.

	/s/ Susan Alpert	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)